Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Angelina L P Pieters, Tjeerd van der Veer, Jennifer J Meerburg, Eleni-Rosalina Andrinopoulou, Menno M Vd Eerden, Pierluigi Ciet, Stefano Aliberti, Pierre-Regis Burgel, Megan L Crichton, Amelia Shoemark, Pieter C Goeminne, Michal Shteinberg, Michael R Loebinger, Charles S Haworth, Francesco Blasi, Harm Awm Tiddens, Daan Caudri, James D Chalmers
RATIONALE: Chest computed tomography -scans (CTs) are essential to diagnose and monitor bronchiectasis (BE). To date, little quantitative data is available about the nature and extent of structural lung abnormalities (SLA) on CTs of BE patients. OBJECTIVES: to investigate SLA on CTs of patients with bronchiectasis and the relationship of SLAs to clinical features using the European Bronchiectasis Registry (EMBARC) Methods: CTs from BE patients included in the EMBARC registry were analyzed using the validated Bronchiectasis Scoring Technique for CT (BEST-CT)...
April 18, 2024: American Journal of Respiratory and Critical Care Medicine
#2
JOURNAL ARTICLE
Arietta Spinou, Beatriz Hererro-Cortina, Stefano Aliberti, Pieter C Goeminne, Eva Polverino, Katerina Dimakou, Charles S Haworth, Michael R Loebinger, Anthony De Soyza, Montserrat Vendrell, Pierre Regis Burgel, Melissa McDonnell, Sivagurunathan Sutharsan, Sabina Skrgat, Luiz Maiz-Carro, Oriol Sibila, Daiana Stolz, Paula Kauppi, Apostolos Bossios, Adam T Hill, Ian Clifton, Megan L Crichton, Paul Walker, Rosario Menendez, Sermin Borecki, Dusanka Obradovic, Adam Nowinski, Adelina Amorim, Antoni Torres, Natalie Lorent, Tobias Welte, Francesco Blasi, Mateja Jankovic Makek, Michal Shteinberg, Wim Boersma, J Stuart Elborn, James D Chalmers, Felix C Ringshausen
BACKGROUND: International guidelines recommend airway clearance management as one of the important pillars of bronchiectasis treatment. However, the extent to which airway clearance is used for people with bronchiectasis in Europe is unclear. The aim of the study was to identify the use of airway clearance management in patients with bronchiectasis across different countries and factors influencing airway clearance use. METHODS: Prospective observational study using data from the EMBARC Registry between January 2015 and April 2022...
April 12, 2024: European Respiratory Journal
#3
JOURNAL ARTICLE
Stefano Aliberti, Felix C Ringshausen, Raja Dhar, Charles S Haworth, Michael R Loebinger, Katerina Dimakou, Megan L Crichton, Anthony De Soyza, Montse Vendrell, Pierre-Regis Burgel, Melissa McDonnell, Sabina Skrgat, Luis Maiz Carro, Andres de Roux, Oriol Sibila, Apostolos Bossios, Menno van der Eerden, Paula Kauppi, Robert Wilson, Branislava Milenkovic, Rosario Menendez, Marlene Murris, Sermin Borekci, Oxana Munteanu, Dusanka Obradovic, Adam Nowinski, Adelina Amorim, Antoni Torres, Natalie Lorent, Eva Van Braeckel, Josje Altenburg, Amelia Shoemark, Michal Shteinberg, Wim Boersma, Pieter C Goeminne, J Stuart Elborn, Adam T Hill, Tobias Welte, Francesco Blasi, Eva Polverino, James D Chalmers
INTRODUCTION: A validated 4-point sputum colour chart can be used to objectively evaluate the levels of airway inflammation in bronchiectasis patients. In the EMBARC registry, we tested whether sputum colour would be associated with disease severity and clinical outcomes. METHODS: Prospective, observational registry of adults with bronchiectasis conducted in 31 countries. Patients who did not produce spontaneous sputum were excluded from the analysis. The Murray sputum colour chart was used at baseline and at follow-up visits...
April 12, 2024: European Respiratory Journal
#4
JOURNAL ARTICLE
Samantha G Dean, Rebekah A Blakney, Emily E Ricotta, James D Chalmers, Sameer S Kadri, Kenneth N Olivier, D Rebecca Prevots
BACKGROUND: Bronchiectasis is a pulmonary disease characterized by irreversible dilation of the bronchi and recurring respiratory infections. Few studies have described the microbiology and prevalence of infections in large patient populations outside of specialized tertiary care centers. METHODS: We used the Cerner HealthFacts Electronic Health Record database to characterize the nature, burden, and frequency of pulmonary infections among persons with bronchiectasis...
April 10, 2024: BMC Pulmonary Medicine
#5
JOURNAL ARTICLE
Felicity Liew, Claudia Efstathiou, Sara Fontanella, Matthew Richardson, Ruth Saunders, Dawid Swieboda, Jasmin K Sidhu, Stephanie Ascough, Shona C Moore, Noura Mohamed, Jose Nunag, Clara King, Olivia C Leavy, Omer Elneima, Hamish J C McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Victoria C Harris, Linzy Houchen-Wolloff, Neil J Greening, Nazir I Lone, Matthew Thorpe, A A Roger Thompson, Sarah L Rowland-Jones, Annemarie B Docherty, James D Chalmers, Ling-Pei Ho, Alexander Horsley, Betty Raman, Krisnah Poinasamy, Michael Marks, Onn Min Kon, Luke S Howard, Daniel G Wootton, Jennifer K Quint, Thushan I de Silva, Antonia Ho, Christopher Chiu, Ewen M Harrison, William Greenhalf, J Kenneth Baillie, Malcolm G Semple, Lance Turtle, Rachael A Evans, Louise V Wain, Christopher Brightling, Ryan S Thwaites, Peter J M Openshaw
One in ten severe acute respiratory syndrome coronavirus 2 infections result in prolonged symptoms termed long coronavirus disease (COVID), yet disease phenotypes and mechanisms are poorly understood1 . Here we profiled 368 plasma proteins in 657 participants ≥3 months following hospitalization. Of these, 426 had at least one long COVID symptom and 233 had fully recovered. Elevated markers of myeloid inflammation and complement activation were associated with long COVID. IL-1R2, MATN2 and COLEC12 were associated with cardiorespiratory symptoms, fatigue and anxiety/depression; MATN2, CSF3 and C1QA were elevated in gastrointestinal symptoms and C1QA was elevated in cognitive impairment...
April 2024: Nature Immunology
#6
JOURNAL ARTICLE
James D Chalmers, Anthony De Soyza, Stefano Aliberti, Eva Polverino
No abstract text is available yet for this article.
April 5, 2024: American Journal of Respiratory and Critical Care Medicine
#7
JOURNAL ARTICLE
Amelia M Burch, Joshua D Garcia, Heather O'Leary, Ami Haas, James E Orfila, Erika Tiemeier, Nicholas Chalmers, Katharine R Smith, Nidia Quillinan, Paco S Herson
Excitotoxicity and the concurrent loss of inhibition are well-defined mechanisms driving acute elevation in excitatory/ inhibitory (E/I) balance and neuronal cell death following an ischemic insult to the brain. Despite the high prevalence of long-term disability in survivors of global cerebral ischemia (GCI) as a consequence of cardiac arrest, it remains unclear whether E/I imbalance persists beyond the acute phase and negatively affects functional recovery. We previously demonstrated sustained impairment of long-term potentiation (LTP) in hippocampal CA1 neurons correlating with deficits in learning and memory tasks in a murine model of cardiac arrest/ cardiopulmonary resuscitation (CA/CPR)...
April 2, 2024: Journal of Neuroscience
#8
JOURNAL ARTICLE
James D Chalmers, Philipp Badorrek, Claudia Diefenbach, Harald Kögler, Wiebke Sauter, Stefan Kreideweiss, Jens M Hohlfeld
Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.
March 2024: ERJ Open Research
#9
JOURNAL ARTICLE
Merete B Long, Hani Abo-Leyah, Yan Hui Giam, Thenmalar Vadiveloo, Rebecca C Hull, Holly R Keir, Thomas Pembridge, Daniela Alferes De Lima, Lilia Delgado, Sarah K Inglis, Chloe Hughes, Amy Gilmour, Marek Gierlinski, Benjamin J M New, Graeme MacLennan, Albena T Dinkova-Kostova, James D Chalmers
INTRODUCTION: Sulforaphane can induce the transcription factor, Nrf2, promoting antioxidant and anti-inflammatory responses. In this study, hospitalised patients with community-acquired pneumonia (CAP) were treated with stabilised synthetic sulforaphane (SFX-01) to evaluate impact on clinical status and inflammation. METHODS: Double-blind, randomised, placebo-controlled trial of SFX-01 (300 mg oral capsule, once daily for 14 days) conducted in Dundee, UK, between November 2020 and May 2021...
March 2024: ERJ Open Research
#10
JOURNAL ARTICLE
Ilona Rosenboom, Ajith Thavarasa, Hollian Richardson, Merete B Long, Lutz Wiehlmann, Colin F Davenport, Amelia Shoemark, James D Chalmers, Burkhard Tümmler
BACKGROUND: The microbiota in the sputum of people with bronchiectasis has repeatedly been investigated in cohorts of different geographic origin, but so far has not been studied to the species level in comparison to control populations including healthy adults and smokers without lung disease. METHODS: The microbial metagenome from sputa of 101 European Bronchiectasis Registry (EMBARC) study participants was examined by using whole-genome shotgun sequencing. RESULTS: Our analysis of the metagenome of people with bronchiectasis revealed four clusters characterised by a predominance of Haemophilus influenzae , Pseudomonas aeruginosa or polymicrobial communities with varying compositions of nonpathogenic commensals and opportunistic pathogens...
March 2024: ERJ Open Research
#11
JOURNAL ARTICLE
Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, David W Denning, Arunaloke Chakrabarti, Kathirvel Soundappan, Mandeep Garg, Shivaprakash M Rudramurthy, Sahajal Dhooria, Darius Armstrong-James, Koichiro Asano, Jean-Pierre Gangneux, Sanjay H Chotirmall, Helmut J F Salzer, James D Chalmers, Cendrine Godet, Marcus Joest, Iain Page, Parameswaran Nair, P Arjun, Raja Dhar, Kana Ram Jat, Geethu Joe, Uma Maheswari Krishnaswamy, Joseph L Mathew, Venkata Nagarjuna Maturu, Anant Mohan, Alok Nath, Dharmesh Patel, Jayanthi Savio, Puneet Saxena, Rajeev Soman, Balamugesh Thangakunam, Caroline G Baxter, Felix Bongomin, William J Calhoun, Oliver A Cornely, Jo A Douglass, Chris Kosmidis, Jacques F Meis, Richard Moss, Alessandro C Pasqualotto, Danila Seidel, Rosanne Sprute, Kuruswamy Thurai Prasad, Ashutosh N Aggarwal
BACKGROUND: The ISHAM working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) nearly a decade ago. There is a need to update these recommendations due to advances in diagnostics and therapeutics. METHODS: An international expert group was convened to develop guidelines for managing ABPA (caused by Aspergillus spp.) and allergic bronchopulmonary mycosis (ABPM, fungi other than Aspergillus spp.) in adults and children using a modified Delphi method (two online rounds and one in-person meeting)...
March 7, 2024: European Respiratory Journal
#12
JOURNAL ARTICLE
Naomi Shek, Anna-Maria Choy, Chim C Lang, Bruce E Miller, Ruth Tal-Singer, Charlotte E Bolton, Neil C Thomson, James D Chalmers, Matt J Bown, David E Newby, Faisel Khan, Jeffrey T J Huang
Aging is a major driving force for many diseases but the relationship between chronological age, the aging process and age-related diseases is not fully understood. Fragmentation and loss of ultra-long-lived elastin are key features in aging and several age-related diseases leading to increased mortality. By comparing the relationship between age and elastin turnover with healthy volunteers, we show that accelerated elastin turnover by age-disease interaction is a common feature of age-related diseases.
February 27, 2024: NPJ Aging
#13
JOURNAL ARTICLE
Yong-Hua Gao, Hai-Wen Lu, Hui-Zhen Zheng, Chao Cao, De-Jie Chu, Hong Fan, Xiao-Yun Fan, Hong-Yan Gu, Wei-Jie Guan, Zhi-Jun Jie, Yang Jin, Wen Li, Yu-Ping Li, Yuan-Yuan Li, Lin Liu, Xue-Dong Liu, Hong Luo, Xiao-Dong Lv, Wei-Qiang Mo, Yuan-Lin Song, Dao-Xin Wang, Ling-Wei Wang, Chang-Zheng Wang, Min Xie, Min Zhang, Cui-Xia Zheng, Bei Mao, Sanjay H Chotirmall, James D Chalmers, Jie-Ming Qu, Jin-Fu Xu
Chronic Pseudomonas aeruginosa (PA) infection significantly contributes to morbidity and mortality in bronchiectasis patients. Initiating antibiotics early may lead to the eradication of PA. Here we outline the design of a trial (ERASE; NCT06093191) assessing the efficacy and safety of inhaled tobramycin, alone or with oral ciprofloxacin, in bronchiectasis patients with a new isolation of PA. This multicentre, 2×2 factorial randomised, double-blind, placebo-controlled, parallel-group trial includes a 2-week screening period, a 12-week treatment phase (with a combination of ciprofloxacin or a placebo at initial 2 weeks) and a 24-week follow-up...
January 2024: ERJ Open Research
#14
JOURNAL ARTICLE
Ashenafi H Betrie, Alaa Abdul-Ridha, Herodion Hartono, David K Chalmers, Christine E Wright, Daniel J Scott, James A Angus, Scott Ayton
Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) is an antimicrobial agent whose actions as a zinc or copper ionophore and an iron chelator revived the interest in similar compounds for the treatment of fungal and bacterial infections, neurodegeneration and cancer. Recently, we reported zinc ionophores, including clioquinol, cause vasorelaxation in isolated arteries through mechanisms that involve sensory nerves, endothelium and vascular smooth muscle. Here, we report that clioquinol also uniquely acts as a competitive alpha-1 (α1 ) adrenoceptor antagonist...
February 24, 2024: Biochemical Pharmacology
#15
JOURNAL ARTICLE
Eva Polverino, Katerina Dimakou, Letizia Traversi, Apostolos Bossios, Charles S Haworth, Michael R Loebinger, Anthony De Soyza, Montserrat Vendrell, Pierre-Régis Burgel, Pontus Mertsch, Melissa McDonnell, Sabina Škrgat, Luis M Carro, Oriol Sibila, Menno van der Eerden, Paula Kauppi, Adam T Hill, Robert Wilson, Branislava Milenkovic, Rosario Menendez, Marlene Murris, Tonia Digalaki, Megan L Crichton, Sermin Borecki, Dusanka Obradovic, Adam Nowinski, Adelina Amorim, Antoni Torres, Natalie Lorent, Tobias Welte, Francesco Blasi, Eva Van Braeckel, Josje Altenburg, Amelia Shoemark, Michal Shteinberg, Wim Boersma, J Stuart Elborn, Stefano Aliberti, Felix C Ringshausen, James D Chalmers, Pieter C Goeminne
BACKGROUND: Asthma is commonly reported in patients with a diagnosis of bronchiectasis. OBJECTIVE: The aim of this study was to evaluate if patients with asthma and bronchiectasis had a different clinical phenotype and different outcomes compared to patients with bronchiectasis without concomitant asthma. METHODS: Prospective observational pan-European registry (EMBARC) enrolling patients across 28 countries. Adult patients with CT confirmed bronchiectasis were reviewed at baseline and annual follow-up visits using an electronic case report form...
February 22, 2024: Journal of Allergy and Clinical Immunology
#16
EDITORIAL
Steven L Taylor, Aurélie Crabbé, Luke R Hoffman, James D Chalmers, Geraint B Rogers
No abstract text is available yet for this article.
February 2024: European Respiratory Journal
#17
JOURNAL ARTICLE
James B Chen, Tracy M Borsinger, Brian P Chalmers, Eytan M Debbi
Total joint replacement (TJR) surgery in the ambulatory surgery centers (ASCs) has grown significantly over the past several years, along with the ability to improve the value of care. Standardization of high-quality, perioperative care is pivotal to the success of a TJR ASC program. As surgeons are experiencing increasing overhead with decreasing reimbursement, technology integration can provide major advantages. In this article, we will therefore highlight several examples of technologies that are changing the field and improving care in the preoperative, intraoperative, and postoperative settings...
February 2024: HSS Journal: the Musculoskeletal Journal of Hospital for Special Surgery
#18
JOURNAL ARTICLE
Min Jun, James Wick, Brendon L Neuen, Sradha Kotwal, Sunil V Badve, Mark Woodward, John Chalmers, David Peiris, Anthony Rodgers, Kellie Nallaiah, Meg J Jardine, Vlado Perkovic, Martin Gallagher, Paul E Ronksley
INTRODUCTION: The prevalence of chronic kidney disease (CKD) in Australia varies substantially across reports. Using a large, nationally representative general practice data source, we determined the contemporary prevalence and staging of CKD in the Australian primary care. METHODS: We performed a retrospective, community-based observational study of 2,720,529 adults with ≥1 visit to a general practice participating in the MedicineInsight program and ≥1 serum creatinine measurement (with or without a urine albumin-to-creatinine ratio [UACR] measurement) between 2011 and 2020...
February 2024: KI Reports
#19
JOURNAL ARTICLE
Ricardo Cordeiro, Hayoung Choi, Charles S Haworth, James D Chalmers
BACKGROUND: Inhaled antibiotics are conditionally recommended by international bronchiectasis guidelines for the treatment of patients with bronchiectasis but results of individual studies are inconsistent. A previous meta-analysis demonstrated promising results regarding the efficacy and safety of inhaled antibiotics in bronchiectasis. Subsequent publications have further supplemented the existing body of evidence in this area. RESEARCH QUESTION: To what extent do inhaled antibiotics demonstrate both efficacy and safety as a treatment option for adults with bronchiectasis? STUDY DESIGN AND METHODS: Systematic review and meta-analysis of randomised controlled trials of inhaled antibiotics in adult patients with bronchiectasis...
February 1, 2024: Chest
#20
JOURNAL ARTICLE
Mariana Conceição, Michal Shteinberg, Pieter Goeminne, Josje Altenburg, James D Chalmers
INTRODUCTION: Pseudomonas aeruginosa is the most commonly isolated pathogen in bronchiectasis and is associated with worse outcomes. Eradication treatment is recommended by guidelines, but the evidence base is limited. The expected success rate of eradication in clinical practice is not known. METHODS: We conducted a systematic review and meta-analysis according to Meta-Analysis of Observational Studies in Epidemiology guidelines. PubMed, Embase, the Cochrane Database of Systematic Reviews and Clinicaltrials...
January 31, 2024: European Respiratory Review: An Official Journal of the European Respiratory Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
